United Therapeutic (UTHR) Stock Price, Quote & News

Company Profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated wit...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 608 9292

Website: www.unither.com

Address:

1000 Spring Street, Silver Spring, United States

Gambaa May. 13 at 10:42 AM

$UTHR space drugs! 🤡🤡🤡

0 · Reply

Quantumup May. 12 at 8:54 PM

BofA last night⬆️ $LQDA's PT to $64 (was $44), plus⬆️Yutrepia's peak sales estimates +40% to $1.7B while reiterating at Buy in its 1Q26 EPS wrap. $UTHR - MKND $INSM Here's what BofA had to say in its note to investors: https://x.com/Quantumup1/status/2054303381431505331?s=20

0 · Reply

DrJOS May. 12 at 3:55 PM

$DDD $UTHR I still believe that DDD did some kind of revenue recognition on the lung project that might explain the great gross margin, higher than expected sales, and the now two big customers of 17% and 10%. I see an increase of receivables on DDD side and an increase of payables on UTHR side. The 17% customer would fit the USD 16m other r&d expense that I attribute to a milestone DDD might meet and recognized in q1. However, I admit that those indications are very uncertain.

0 · Reply

JFais May. 12 at 12:27 PM

$LQDA moved up to my #3 position after yesterday's move (even after partial profits in March for risk mgmt into judge ruling) Boring plan as always, holding patiently for accelerating clinical & commercial momentum (continue to see tolerability as big advantage vs $UTHR $INSM)

0 · Reply

Quantumup May. 12 at 10:55 AM

Wells Fargo y'day⬆️ $LQDA's PT to $62 (was $51), reiterated Overweight, ans said: Yutrepia appears to be disrupting the PAH/PH-ILD market, and we anticipate this level of growth continues through 2Q26. $UTHR MNKD $INSM Wells Fargo added—We're raising our PT to $62/shr as we lift our near-term Yutrepia est., and we now include risk-adjusted value for L606 in IPF. Stock setup. Shares are up significantly on the day (+25.6% vs XBI of +0.03%), we think driven by the strong Yutrepia sales, which is concordant with weaker-than-expected Tyvaso. We think this has added conviction for Yutrepia to drive significant earnings growth. We believe Yutrepia is likely out-competing Tyvaso for new patients, and possibly also taking share from Tyvaso nebulizer. It doesn't seem likely that growth will slow near term, and therefore we expect further share capture in 2Q26.

0 · Reply

Quantumup May. 11 at 5:24 PM

BTIG⬆️ $LQDA's PT to $59, reiterated at Buy, and said:::Yutrepia's launch is continuing as one of the top drug launches in any category across the last 5 years. $UTHR MNKD $INSM Here's what else BTIG had to say: https://x.com/Quantumup1/status/2053888081065837030?s=20

0 · Reply

DrJOS May. 11 at 4:33 PM

$DDD there is a pretty chance in my eyes that $UTHR paid up to $15M to DDD in q1 26. Look at UTHR 10q last week! It reads "The fair value of our contingent consideration liabilities increased by $1.7 million during the period from December 31, 2025 to March 31, 2026." but they incurred $16.7m for milestones payments and fair value of contingent consideration. If I am right, revenue and gross margin would be far better than expected. I am strongly invested.

2 · Reply

clan May. 11 at 3:51 PM

$MNKD $UTHR No dilly-dallying around. Everbody gets a priority review! Sooner, rather than later. It's Go Time!

0 · Reply

clan May. 11 at 2:08 PM

$UTHR Unither's new production facility in NC has always been, and remains primarily, a DPI facility. To pump out BILLIONS of DOLLARS of Technosphere dry powder inhalation per year in the form of Ralinepag DPI. It wasn't built for mist production needs. Not for pigs hearts. Not for other 3-D organs. It's going to be used to manufacture RALDPI that will generate BILLIONS of zero-cost Royalties for Mannkind over the coming years. Billions. For the good of all $MNKD

0 · Reply

clan May. 11 at 1:38 PM

$MNKD >$600M Revs for 2027? With kids, preggos, India, IPF, Autoinjector,... Could be. $BX $UTHR

1 · Reply

United Therapeutics, Varda Space Industries team on use of microgravity

May 12, 2026, 7:00 AM EDT - 1 day ago

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

2026-05-11T11:20:41.000Z - 2 days ago

United Therapeutics to present positive data of treprostinil in IPF

May 11, 2026, 6:30 AM EDT - 2 days ago

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

2026-05-07T19:01:05.000Z - 5 days ago

United Therapeutics price target lowered to $516 from $519 at Morgan Stanley

2026-05-07T12:19:06.000Z - 6 days ago

United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

2026-05-07T11:42:13.000Z - 6 days ago

United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

2026-05-07T09:22:42.000Z - 6 days ago

United Therapeutics reports Q1 EPS $5.82, consensus $6.86

2026-05-07T09:21:34.000Z - 6 days ago

United Therapeutics reports Q1 EPS $5.82, consensus $6.86

May 6, 2026, 9:00 AM EDT - 7 days ago

United Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 6:30 AM EDT - 7 days ago

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

2026-04-29T13:08:31.000Z - 14 days ago

United Therapeutics announces retirement of Professor Dwek from board

Apr 29, 2026, 7:00 AM EDT - 14 days ago

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

Apr 22, 2026, 7:00 AM EDT - 21 days ago

United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

Apr 20, 2026, 6:30 AM EDT - 23 days ago

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

2026-04-10T12:57:05.000Z - 4 weeks ago

United Therapeutics price target raised to $519 from $471 at Morgan Stanley

2026-04-10T09:40:13.000Z - 4 weeks ago

United Therapeutics initiated with an Outperform at Raymond James

2026-04-09T20:31:09.000Z - 4 weeks ago

United Therapeutics initiated with an Outperform at Raymond James

2026-04-08T11:16:05.000Z - 5 weeks ago

United Therapeutics announces FDA granted RMAT designation to miroliverELAP

Apr 8, 2026, 7:00 AM EDT - 5 weeks ago

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

2026-04-07T15:03:10.000Z - 5 weeks ago

United Therapeutics price target raised to $700 from $643 at RBC Capital

2026-03-31T14:43:37.000Z - 6 weeks ago

United Therapeutics price target raised to $660 from $600 at H.C. Wainwright

2026-03-31T10:53:06.000Z - 6 weeks ago

United Therapeutics price target raised to $626 from $569 at BofA

2026-03-31T10:39:24.000Z - 6 weeks ago

United Therapeutics price target raised to $575 from $486 at Wells Fargo

Mar 30, 2026, 7:00 AM EDT - 6 weeks ago

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

Mar 11, 2026, 6:14 PM EDT - 2 months ago

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

Mar 9, 2026, 1:00 PM EDT - 2 months ago

United Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 2 months ago

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

Mar 3, 2026, 7:00 AM EST - 2 months ago

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

Mar 2, 2026, 2:30 PM EST - 2 months ago

United Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

United Therapeutics Transcript: Study result

Mar 2, 2026, 6:38 AM EST - 2 months ago

United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study

Mar 2, 2026, 6:30 AM EST - 2 months ago

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

Feb 25, 2026, 9:00 AM EST - 2 months ago

United Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 6:30 AM EST - 2 months ago

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 7:00 AM EST - 2 months ago

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 7:00 AM EST - 3 months ago

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

Jan 26, 2026, 7:00 AM EST - 3 months ago

United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure

Jan 22, 2026, 7:00 AM EST - 3 months ago

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

Jan 12, 2026, 4:30 PM EST - 4 months ago

United Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 3:57 PM EST - 4 months ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN MNKD NVDA OMC

Jan 5, 2026, 7:00 AM EST - 4 months ago

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 7:19 AM EST - 5 months ago

Flurry of Bullish Inflows Sends United Therapeutics Higher

Nov 18, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 6 months ago

United Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Corporation to Present at Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

Oct 29, 2025, 9:00 AM EDT - 7 months ago

United Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 6:30 AM EDT - 7 months ago

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

Oct 15, 2025, 7:00 AM EDT - 7 months ago

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

Oct 13, 2025, 7:00 AM EDT - 7 months ago

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

Sep 28, 2025, 12:30 PM EDT - 8 months ago

United Therapeutics Transcript: Study Update

Sep 23, 2025, 1:10 PM EDT - 8 months ago

United Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 19, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

Sep 16, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

Sep 12, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

Sep 8, 2025, 3:20 PM EDT - 8 months ago

United Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 10:10 AM EDT - 9 months ago

United Therapeutics: Is UTHR Stock Still A Buy At $400?

Sep 2, 2025, 10:09 AM EDT - 9 months ago

United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest?

Sep 2, 2025, 9:17 AM EDT - 9 months ago

United Therapeutics shares surge on successful late-stage lung disease study

Sep 2, 2025, 7:00 AM EDT - 9 months ago

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

Aug 29, 2025, 7:00 AM EDT - 9 months ago

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 1, 2025, 7:00 AM EDT - 10 months ago

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Jul 30, 2025, 9:00 AM EDT - 10 months ago

United Therapeutics Earnings Call Transcript: Q2 2025

Jul 30, 2025, 6:30 AM EDT - 10 months ago

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results

Jul 16, 2025, 7:00 AM EDT - 10 months ago

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

Jun 24, 2025, 7:00 AM EDT - 11 months ago

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

Jun 23, 2025, 7:00 AM EDT - 11 months ago

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

Apr 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q1 2025

Apr 30, 2025, 6:30 AM EDT - 1 year ago

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 1 year ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

Apr 4, 2025, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

Mar 11, 2025, 10:00 AM EDT - 1 year ago

United Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

Mar 3, 2025, 1:50 PM EST - 1 year ago

United Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

United Therapeutics Earnings Call Transcript: Q4 2024

Feb 26, 2025, 6:30 AM EST - 1 year ago

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Feb 3, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

Jan 21, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 13, 2025, 5:15 PM EST - 1 year ago

United Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Gambaa May. 13 at 10:42 AM

$UTHR space drugs! 🤡🤡🤡

0 · Reply

Quantumup May. 12 at 8:54 PM

0 · Reply

DrJOS May. 12 at 3:55 PM

0 · Reply

JFais May. 12 at 12:27 PM

0 · Reply

Quantumup May. 12 at 10:55 AM

0 · Reply

Quantumup May. 11 at 5:24 PM

0 · Reply

DrJOS May. 11 at 4:33 PM

2 · Reply

clan May. 11 at 3:51 PM

$MNKD $UTHR No dilly-dallying around. Everbody gets a priority review! Sooner, rather than later. It's Go Time!

0 · Reply

clan May. 11 at 2:08 PM

0 · Reply

clan May. 11 at 1:38 PM

$MNKD >$600M Revs for 2027? With kids, preggos, India, IPF, Autoinjector,... Could be. $BX $UTHR

1 · Reply

JFais May. 11 at 1:05 PM

$LQDA (L) Slight acceleration of unique scripts + patient adds as well as referrals & script to start in March to April New prescribers trial the drug and then begin using Yutrepia preferentially (trigger change) Market share has gone from 10% to 16% to 23% across past 3 quarters! Anecdotal evidence is stacking up- night and day difference on cough and ability to drive outcomes vs $UTHR Tyvaso/DPI PAH & PH-ILD massively underpenetrated, lots of runway to grow the franchise significantly (clear line of site to $6B TAM) PH-COPD is a $4B opportunity in & of itself, will run a study that's enriched for success

0 · Reply

JFais May. 11 at 12:51 PM

$LQDA (L) Slight acceleration of unique scripts + patient adds as well as referrals & script to start in March to April New prescribers trial the drug and then begin using Yutrepia preferentially (trigger change) Anecdotal evidence stacking up- night and day difference on cough and ability to drive outcomes vs $UTHR Tyvaso/DPI PAH & PH-ILD massively underpenetrated, lots of runway to grow the franchise significantly (clear line of site to $6B TAM)

0 · Reply

Affizle May. 11 at 11:36 AM

$LQDA If $UTHR 's CEO Martin(e) really wanted to corner the market on PAH, PAH-ILD, and IPF, he should just buy LQDA for between 5-8 billion dollars.

2 · Reply

clan May. 10 at 7:06 PM

$MNKD $UTHR "Blockbuster"

1 · Reply

BioTechHealthX May. 10 at 4:56 PM

$UTHR United Therapeutics reported a slight revenue decline in Q1 2026, but positive clinical updates from ADVANCE OUTCOMES and TETON-1 could keep investors watching. With Tyvaso DPI growth, Orenitram momentum, and a focused respiratory disease portfolio, UTHR remains a biotech stock with more going on beneath the surface. https://biotechhealthx.com/biotech-news/is-it-a-good-move-to-invest-in-united-therapeutics-uthr/

0 · Reply

BioTechHealthX May. 10 at 4:31 AM

$ARGX $MRNA $UTHR $VRTX $DHR Biotech stocks can move fast when clinical trials, FDA approvals, product sales, and investor momentum line up. These top 5 best biotech stocks to watch now could attract attention as healthcare innovation heats up in 2026. https://biotechhealthx.com/biotech-news/top-5-best-biotech-stocks-to-watch-now/

1 · Reply

Kool_Aid_Mann May. 8 at 7:46 PM

$GME $AMC Come join $MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but it is finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner $UTHR . Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! Fireworks ahead, fight the Citadel!

1 · Reply

TheLastKings May. 8 at 1:36 AM

$UTHR Royalty payments coming soon or no?

0 · Reply

clan May. 7 at 6:44 PM

$MNKD $UTHR Symbiotic relationship. 💪

0 · Reply

kcphaeton May. 7 at 2:17 AM

$UTHR $MNKD she probably had her panties in a wad and couldn’t think straight.

0 · Reply

kcphaeton May. 7 at 2:15 AM

$MNKD $UTHR interesting observation. I only wish that Mannkind had the guts to up the anti with them.

2 · Reply

ssaq May. 7 at 1:34 AM

$MNKD If we strip everything out of $MNKD, the pipeline, afrezza, tyvaso dpi, ip, the factory, everything. And we focus on just the new news $UTHR announced this morning. That's the bridge study for tyvaso dpi ipf, and mnkd 1501 for 4 indications. What's the present value of those streams, risk adjusted (including probability of failure). Only that... A good $2.25+ per share to mnkd? A good $700M for both without adding a premium? I feel pretty good that today's news was overwhelmingly positive. And it was very undervalued before this news.

1 · Reply

Market Cap	24.19B
Revenue (ttm)	3.18B
Net Income (ttm)	1.33B
EPS (ttm)	N/A
PE Ratio	20.85
Forward PE	20.62
Profit Margin	41.94%
Debt to Equity Ratio	0.00

Volume	397,400
Avg Vol	574,116
Day's Range	N/A - N/A
Shares Out	42.45M
Stochastic %K	43%
Beta	0.60
Analysts	Strong Sell
Price Target	$663.17